Trubion Pharmaceuticals

In the biggest life science initial public offering on a European exchange since November 2014, Nordic Nanovector grossed NOK 500m ($62.3m) from its IPO on the Oslo stock exchange on 23 March 2015. Th

Updated Phase II results for otlertuzumab from Emergent BioSolutions plus Teva Pharmaceutical's Treanda (bendamustine), which were presented at the American Society of Hematologists (ASH) Annual Meeti

Stock prices for Ambit Biosciences and Emergent BioSolutions dipped after abstracts for their data presentations at the upcoming American Society of Hematologists (ASH) Annual Meeting and Exposition b

Though Abraxane (paclitaxel) is now part of Celgene Corp. 's growing oncology portfolio, you don't need Celgene stock to invest in its newest product, a reformulation of the generic chemotherapy